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ticipated in this study. Of the respondents 55% were females, 69% worked in a 
chain pharmacy, with an average 11 years of work experience. 65% of the respon-
dents were aware of the labeling changes introduced by the FDA. Attitude of phar-
macists towards all the speciﬁc labeling changes introduced for acetaminophen and 
NSAIDs were positive. Pharmacists strongly and signiﬁcantly agreed (p < 0.001) 
that labeling changes like highlighting ingredient name or mentioning it in bold print 
(3.84 ± 1.08), appearance of “See New Warnings” statement on the principal display 
panel for one year (3.96 ± 1.06), age speciﬁc warnings for adults and for children 
below 12 years of age (4.12 ± 1.19), mentioning the maximum daily dosage units 
of acetaminophen under liver warnings (4.31 ± 1.06), will be useful for patients. 
CONCLUSIONS: The results indicate that majority of pharmacists agreed with 
FDA’s labeling changes for OTC IAAA drug products. More information regarding 
these changes should be provided to pharmacists and consumers to increase appro-
priate use of these products.
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OBJECTIVES: Experience indicated that the quality of economic evaluations submit-
ted in reimbursement dossiers and critical appraisals are heterogeneous. The objective 
of this study was to analyse the quality of submitted economic studies and related 
critical appraisal processes and to develop a policy-relevant, publicly available Slovak 
critical appraisal checklist for improving the quality of economic evaluation and 
budget impact analyses for reimbursement submission of dossiers concerning to drugs 
and medical devices. METHODS: We created a working group to review previously 
submitted economic evaluations and related critical appraisals in order to identify 
potential technical and methodological problems. The working group consisted of 
independent academic experts who scrutinized previous submissions and critical 
appraisals and developed a new checklist. Overall 50 economic evaluations submitted 
for reimbursement of drugs and medical devices in 2007–2009 were scrutinized. 
RESULTS: Evidence suggests that Slovak pharmaceutical expenditures do not result 
in the most cost-effective outcomes. Several potentially not cost-effective pharmaceu-
ticals have been reimbursed in Slovakia. Economic evaluations of drugs and medical 
devices are mandatory but the quality of evaluations and critical appraisals are rather 
poor. Therefore in addition to the available Slovak health economic evaluation guide-
lines a detailed checklist for appraisal processes have to be prepared. Our analysis 
shows that the simpliﬁed questionnaire, which is currently used for the critical 
appraisal process within Slovakia should be replaced by a new Slovak critical appraisal 
checklist, which will be detailed enough to address the most common problems in the 
local economic evaluations and budget impact analyses for decision making process. 
CONCLUSIONS: The transparent method of technology assessment can improve the 
consistency of reimbursement decisions making related to drugs and medical devices 
in Slovakia. The current checklist for critical appraisal is not sufﬁcient enough and 
there is signiﬁcant room for improvement in this ﬁeld.
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OBJECTIVES: The objective of this study was to evaluate outcomes of a bedside 
barcode technology intervention on medication administration time in an intensive 
care unit (ICU). METHODS: A prospective observational time-and-motion experi-
mental study was conducted by considering two medication administration processes 
(a paper based approach vs. the bedside barcode system) in a large 500+ bed hospital 
setting. Medication administration by the nurse was operationalized as activities such 
as direct or indirect patient care, administration, and miscellaneous. Time devoted to 
complete these medication administration activities were measured separately by 
means of two pre-calibrated stop watches. Complexity factors of medication admin-
istration (age, sex, body-weight, comorbidities, number of drugs administered, and 
length of ICU stay) were included in linear regression model to predict time required 
for each of those medication administration activities. RESULTS: One hundred and 
ﬁfty-one electronically documented medication administrations with the bedside 
barcode system were evaluated Mean times of direct patient care activity (182.32 ± 
131.68 seconds) and administration activity (59.83 ± 74.53 seconds) during bedside 
barcode medication administration improved signiﬁcantly in comparison with paper 
based approach. In the bedside barcode system, signiﬁcant (p < 0.05) predictors of 
time associated with direct patient care activity was number of drugs administered, 
for indirect patient care activity was comorbidities, and for administration activity 
was length of ICU stay. CONCLUSIONS: Variables that predict medication admin-
istration time in the bedside barcode system were different across the categorized 
activities. To develop and implement efﬁcient systems, such variables should be moni-
tored and controlled as high cost technology is adopted by hospitals.
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OBJECTIVES: A goal of evidence review is to inform policy decisions such as for 
insurance. This study examines whether and how U.S. payers use evidence reviews in 
policy decisions for personalized medicine. METHODS: We used literature review, 
focused interviews and a Roundtable meeting. Literature review was used to review 
and compare seven evaluation frameworks available to guide payer decisions: Blue 
Cross Blue Shield Technology Evaluation Center (BCBS TEC); ECRI Institute, Evalu-
ation of Genomic Applications in Practice and Prevention, Institute for Clinical and 
Economic Review, Hayes, Inc., Up-To-Date and United States Preventive Services Task 
Force. Seventeen interviews of health plan executives were used to identify whether 
and how these frameworks were used in policy decisions made by individual plans. A 
meeting that included interviewees and other thought leaders was used to discuss 
similarities and differences across payers in whether and how formal evaluations 
informed policy. The study focused on personalized medicine, the use of genetics or 
genomics to guide health care decisions. RESULTS: We found that frameworks vary 
in: purpose, questions of interest, range of evidence included, availability, and capac-
ity. All frameworks were used by at least one payer to inform policy decisions with 
one framework (BCBS TEC) used by all but one interviewed payer. All payers reported 
using multiple frameworks. Payers reported key gaps in frameworks including: lack 
of evidence on health care system factors, lack of timeliness and lack of breadth. 
Across payers the range of evidence used to inform decisions was believed to result in 
policy variation. In particular, when clinical evidence is uncertain but decisions 
needed, payers reported using nonclincal evidence to help guide decisions. CONCLU-
SIONS: Payers use evidence reviews to inform policy decisions but no single frame-
work is sufﬁcient. Key ways to improve reviews for insurance policy decisions might 
focus on balancing the tension between comprehensiveness and timeliness.
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OBJECTIVES: Health technology assessment (HTA) is used to evaluate health care 
technologies (e.g., pharmaceuticals, medical devices, and diagnostics) with respect to 
cost and their projected impact on patient outcomes and society. Currently, there is 
an ongoing initiative by the International Society for Pharmacoeconomics and Out-
comes Research (ISPOR) to develop Road Maps that describe the utilization of HTA 
in health care. The purpose of this study was to develop models for HTA decision-
making structures along with reimbursement road maps for several countries. 
METHODS: Members of the ISPOR Special Interest Group (SIG) for HTA contacted 
key individuals in several countries, including: Austria, Demark, Hungary, Ireland, 
France, Germany, Denmark, UK, Sweden, Australia, Canada, Taiwan, United States, 
and others. Once decision models and corresponding reimbursement road maps were 
developed within designated HTA subgroups, the information was disseminated to all 
HTA committee members for review. After review, the decision models were sent to 
key stakeholders in each selected country for review and validation. RESULTS: Deci-
sion-making structures and review processes for reimbursement were developed for 
the selected counties. Key decision makers and/or third-party payers (e.g., person or 
organization) were identiﬁed and deﬁned in accordance with their role in the reim-
bursement process. Evaluators were deﬁned as individuals or organizations that 
provide input into the decision-making process regarding HTA development, but may 
not be responsible for ﬁnal coverage and payment decisions. CONCLUSIONS: Deci-
sion structures for reimbursement (e.g., coverage, coding, and payment) vary accord-
ing to the type of product (e.g., pharmaceutical, medical device, and diagnostic), the 
individual country and in some instances, by regions within the country. The HTA-SIG 
will continue to identify and validate HTA decision pathways for reimbursement 
within each country to provide guidance to manufacturers and policy makers in a way 
that optimizes efﬁciencies and supports the ongoing societal needs for access to emerg-
ing technologies.
PHP87
DECISION CRITERIA FOR TECHNOLOGY ACQUISITION IN 
RADIOONCOLOGY—WHAT REALLY MATTERS?
Gurtner S1, Uecke O2, Schefczyk M1
1Technische Universität Dresden, Dresden, Sachsen, Germany, 2Max Planck Institute of 
Molecular Cell Biology and Genetics, Dresden, Sachsen, Germany
OBJECTIVES: The assessment of medical technologies in hospitals is often an unstruc-
tured not transparent process, only involving a small group of decision makers. To 
overcome barriers while discussing or implementing decisions, a clear communication 
